

International Non-Proprietary Names for Pharmaceutical Preparations



In accordance with article 3 of the Procedure for the Selection of Recommended International Non-Proprietary Names for Pharmaceutical Preparations,¹ notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Non-Proprietary Names.

Comments on, or formal objections to, the

proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in the *WHO Chronicle*.

The inclusion of a name in the lists of proposed international non-proprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 20²

Proposed International Non-Proprietary Name (Latin, English)	Chemical Name or Description, Molecular and Graphic Formulae
acidum canrenoicum canrenoic acid	17-hydroxy-3-oxo-17 α -pregna-4,6-diene-21-carboxylic acid $C_{22}H_{30}O_4$ 
acidum cicrotoicum cicrotoic acid	β -methylcyclohexaneacrylic acid $C_{10}H_{18}O_2$ 

² See Annex, p. 427.

¹ Other lists of proposed international non-proprietary names can be found in *Chron. Wld Hlth Org.*, 1953, 7, 299; 1954, 8, 216, 313; 1956, 10, 28; 1957, 11, 231; 1958, 12, 102; *WHO Chronicle*, 1959, 13, 105, 152; 1960, 14, 168, 244; 1961, 15, 314; 1962, 16, 385; 1963, 17, 389; 1964, 18, 433; 1965, 19, 446; 1966, 20, 216; 1967, 21, 70, 478, 1968, 22, 112.


Lists of recommended international non-proprietary names were published in *Chron. Wld Hlth Org.*, 1955, 9, 185; *WHO Chronicle*, 1959, 13, 106, 463; 1962, 16, 101; 1965, 19, 165, 206, 249; 1966, 20, 421; 1967, 21, 538.

*Proposed International
Non-Proprietary Name
(Latin, English)*

acidum clofibricum
clofibric acid


*Chemical Name or Description,
Molecular and Graphic Formulae*

2-(p-chlorophenoxy)-2-methylpropionic acid
 $C_{10}H_{11}ClO_3$




acidum clorindanicum
clorindanic acid

7-chloro-4-hydroxy-5-indancarboxylic acid
 $C_{10}H_7ClO_3$




acidum iobutoicum
iobutoic acid

4-[2,4,6-triiodo-3-(morpholinocarbonyl)phenoxy]butyric acid
 $C_{15}H_{15}I_3NO_5$



acidum metiazinicum
metiazinic acid

10-methylphenothiazine-2-acetic acid
 $C_{15}H_{13}NO_2S$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


benmoxinum
benmoxin

benzoic acid 2-(α -methylbenzyl)hydrazide
 $C_{15}H_{14}N_2O$




boldenonum
boldenone

17 β -hydroxyandrosta-1,4-dien-3-one
 $C_{19}H_{24}O_2$




bromhexinum
bromhexine

3,5-dibromo- N^{α} -cyclohexyl- N^{α} -methyltoluene- α -2-diamine
 $C_{14}H_{20}Br_2N_2$



bufexamacum
bufexamac

2-(p -butoxyphenyl)-acetohydroxamic acid
 $C_{12}H_{17}NO_3$




*Proposed International
Non-Proprietary Name
(Latin, English)*

canrenoatum kalium
canrenoate potassium


*Chemical Name or Description,
Molecular and Graphic Formulae*

potassium 3-oxo-17 α -pregna-4,6-diene-21-carboxylate
 $C_{22}H_{28}KO_4$




canrenonum
canrenone

17-hydroxy-3-oxo-17 α -pregna-4,6-diene-21-carboxylic acid γ -lactone
 $C_{22}H_{28}O_3$




carbazochromum
carbazochrome

3-hydroxy-1-methyl-5,6-indolinedione semicarbazone
 $C_{10}H_{12}N_4O_3$



carbenicillinum
carbenicillin

N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-
2-phenylmalonic acid
 $C_{17}H_{16}N_2O_5S$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


cingestolum
cingestol

19-nor-17 α -pregn-5-en-20-yn-17-ol
C₂₆H₄₂O




cletoquinum
cletoquine

2-((4-[(7-chloro-4-quinolyl)amino]pentyl)amino)ethanol
C₁₈H₂₂ClN₃O




clomegestonum
clomegestone

6-chloro-17-hydroxy-16 α -methylpregna-4,6-diene-3,20-dione
C₂₂H₂₈ClO₃



clopidolum
clopidol

3,5-dichloro-2,6-dimethyl-4-pyridinol
C₇H₇Cl₂NO




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


cloprothiazolum
cloprothiazole

5-(3-chloropropyl)-4-methylthiazole
 $C_7H_{10}ClNS$




clotioxonum
clotioxone

2-phenyl-4-[(trichloromethyl)thio]-4^H-1,3,4-oxadiazolin-5-one
 $C_8H_5Cl_3N_2O_2S$




creatinolfosfatum
creatinolfosphate

1-(2-hydroxyethyl)-1-methylguanidine dihydrogen phosphate (ester)
 $C_4H_{12}N_5O_4P$



danazolium
danazol

17 α -pregna-2,4-dien-20-yno[2,3-*d*]isoxazol-17-ol
 $C_{22}H_{27}NO_2$




*Proposed International
Non-Proprietary Name
(Latin, English)*

daunorubicinum
daunorubicin


*Chemical Name or Description,
Molecular and Graphic Formulae*

a glucosidic antibiotic obtained from cultures of *Streptomyces peuce-
ticus* or *Streptomyces coeruleorubidus*, or the same substance obtained
by any other means
 $C_{27}H_{29}NO_{10}$




R^1 or R^2 : $-OCH_3$

R^3 or R^4 :




decoquinatum
decoquinat

ethyl 6-(decyloxy)-7-ethoxy-4-hydroxy-3-quinoline-carboxylate
 $C_{24}H_{35}NO_5$




deprodonum
deprodone

11 β ,17-dihydroxypregna-1,4-diene-3,20-dione
 $C_{21}H_{32}O_4$



desoximetasolum
desoximetasone

9-fluoro-11 β , 21-dihydroxy-16 α -methylpregna-1,4-diene-3,20-dione
 $C_{22}H_{31}FO_4$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


dexivacainum
dexivacaine

(+)-1-methyl-2',6'-pipecoloxylidide
 $C_{15}H_{22}N_2O$




etolorexum
etolorex

2-[(p-chloro- α,α -dimethylphenethyl)amino]ethanol
 $C_{12}H_{15}ClNO$




filipinum
filipin

3,5,7,9,11,13,15,26,27-nonahydroxy-2-(1-hydroxyhexyl)-16-methyl-16,18,
20,22,24-octacosapentaenoic acid 1,27-lactone
 $C_{35}H_{54}O_{11}$



fipexidum
fipexide

1-[(p-chlorophenoxy)acetyl]-4-piperonylpiperazine
 $C_{20}H_{21}ClN_2O_4$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


flualamidum
flualamide

2-(allyloxy)-N-[2-(diethylamino)ethyl]- α,α,α -trifluoro-*p*-toluamide
 $C_{17}H_{23}F_3N_2O_2$




flurazepamum
flurazepam

7-chloro-1-[2-(diethylamino)ethyl]-5-(*o*-fluorophenyl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one
 $C_{21}H_{23}ClFN_2O$




fopirtolinum
fopirtoline

4-[2-[(6-chloro-2-pyridyl)thio]ethyl]morpholine
 $C_{17}H_{19}ClN_2OS$



geroquinolum
geroquinol

2-geranylhydroquinone
 $C_{18}H_{22}O_2$




Proposed International
Non-Proprietary Name
(Latin, English)

Chemical Name or Description,
Molecular and Graphic Formulae


gloxazonum
gloxazone

3-ethoxy-2-oxobutylaldehyde bis(thiosemicarbazone)
 $C_8H_{15}N_6OS_2$




guanadrelum
guanadrel

(1,4-dioxaspiro[4.5]dec-2-ylmethyl)guanidine
 $C_{10}H_{16}N_4O_2$




halofenatum
halofenate

(p-chlorophenyl)[(α,α,α-trifluoro-m-tolyl)oxy]acetic acid ester with *N*-(2-hydroxyethyl)acetamide
 $C_{19}H_{17}ClF_3NO_4$



homopipramolum
homopipramol

4-[3-(5*H*-dibenz[*b,f*]azepin-5-yl)propyl]hexahydro-1*H*-1,4-diazepine-1-ethanol
 $C_{24}H_{31}N_3O$



kalafunginum
kalafungin

an antibiotic obtained from cultures of *Streptomyces tanashiensis* strain *kala*, or the same substance obtained by any other means

lidimycinum
lidimycin


an antibiotic obtained from cultures of *Streptomyces lydicus*, or the same substance obtained by any other means

*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


mecloralurea
mecloralurea

1-methyl-3-(2,2,2-trichloro-1-hydroxyethyl)urea
 $C_4H_7Cl_3N_2O_2$




medazepamum
medazepam

7-chloro-2,3-dihydro-1-methyl-5-phenyl-1*H*-1,4-benzodiazepine
 $C_{16}H_{15}ClN_2$




metampicillinum
metampicillin

3,3-dimethyl-6-[2-(methyleneamino)-2-phenylacetamido]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
 $C_{17}H_{15}N_3O_4S$



metoserpatum
metoserpate

methyl O-methyl-18-epireserpate
 $C_{24}H_{32}N_2O_5$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


mianserinum
mianserin

1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine
 $C_{15}H_{20}N_2$




milipertinum
milipertine

5,6-dimethoxy-3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2-methylindole
 $C_{24}H_{31}N_3O_3$




mitobronitolum
mitobronitol

1,6-dibromo-1,6-dideoxy-D-mannitol
 $C_6H_{12}Br_2O_4$



mitoguazonum
mitoguazone

1,1'-[(methyleneethanediylidene)dinitrilo]diguanidine
 $C_5H_{12}N_8$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


moquizonum
moquizone

2,3-dihydro-1-(morpholinoacetyl)-3-phenyl-4(1*H*)-quinazolinone
 $C_{20}H_{21}N_3O_3$




niclofolanum
niclofolan

4,4'-dichloro-6,6'-dinitro-o,o'-biphenol
 $C_{12}H_6Cl_2N_2O_4$




nifurfolinum
nifurfoline

3-morpholinomethyl)-1-[(5-nitrofurfurylidene)amino]-hydantoin
 $C_{13}H_{13}N_5O_4$



nifurpiponum
nifurpipone

4-methyl-1-piperazineacetic acid (5-nitrofurfurylidene)hydrazide
 $C_{12}H_{17}N_5O_4$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


nifursolum
nifursol

3,5-dinitrosalicylic acid (5-nitrofurfurylidene)hydrazide
 $C_{12}H_7N_5O_6$




nimazonum
nimazone

3-(*p*-chlorophenyl)-4-imino-2-oxo-1-imidazolidineacetonitrile
 $C_{11}H_8ClN_4O$




norfluranum
norflurane

1,1,1,2-tetrafluoroethane
 $C_2H_2F_4$



nortetrazepamum
nortetrazepam

7-chloro-5-(1-cyclohexen-1-yl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one
 $C_{15}H_{13}ClN_2O$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


noxiptilinum
noxiptiline

10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-one *O*-[2-(dimethyl-
amino)ethyl]oxime
 $C_{19}H_{22}N_2O$




orpressinum
orpressin






8-ornithinevasopressin
 $C_{45}H_{63}N_{13}O_{12}S_2$



oxifentorexum
oxifentorex

N-benzyl-*N*, α -dimethylphenethylamine *N*-oxide
 $C_{17}H_{21}NO$




Proposed International Non-Proprietary Name (Latin, English)	Chemical Name or Description, Molecular and Graphic Formulae
oxprenololum oxprenolol	1-(o-allyloxyphenoxy)-3-(isopropylamino)-2-propanol $C_{15}H_{23}NO_3$
	
phoximum phoxim	phenylglyoxynitrile oxime O,O-diethyl phosphorothioate $C_{12}H_{15}N_2O_3PS$
	
pimeclonum pimeclone	2-(piperidinomethyl)cyclohexanone $C_{12}H_{21}NO$
	
pipratecolum pipratecol	α -(3,4-dihydroxyphenyl)-4-(2-methoxyphenyl)-1-piperazineethanol $C_{19}H_{24}N_2O_4$
	
prifinii bromidum prifinium bromide	3-(diphenylmethylene)-1,1-diethyl-2-methylpyrrolidinium bromide $C_{22}H_{28}BrN$
	

Proposed International
Non-Proprietary Name
(Latin, English)

Chemical Name or Description,
Molecular and Graphic Formulae


profadolium
profadol

m-(1-methyl-3-propyl-3-pyrrolidinyl)phenol
 $C_{14}H_{21}NO$




quazodinium
quazodine

4-ethyl-6,7-dimethoxyquinazoline
 $C_{12}H_{14}N_2O_2$



racefenicolum
racefenicol

(±)-*threo*-2,2-dichloro-*N*-[β-hydroxy-α-(hydroxymethyl)-*p*-(methylsulfonyl)phenethyl]acetamide
 $C_{12}H_{13}Cl_2NO_3S$




ranimycinum
ranimycin

an antibiotic obtained from cultures of *Streptomyces lincolnensis*,
or the same substance obtained by any other means
 $C_{12}H_{13}O_6$

riboprimum
riboprine

N-(3-methyl-2-butenyl)adenosine
 $C_{15}H_{21}N_5O_4$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


salbutamolum
salbutamol

α -[[*tert*-butylamino)methyl]-4-hydroxy-*m*-xylene- α,α' -diol
 $C_{13}H_{21}NO_3$




saletamidum
saliatamide

N-[2-(diethylamino)ethyl]salicylamide
 $C_{13}H_{20}N_2O_2$



soterenolum
soterenol

2'-hydroxy-5'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonani-
lide
 $C_{12}H_{20}N_2O_4S$




steffimycinum
steffimycin

an antibiotic obtained from cultures of *Streptomyces steffisburgensis*
var. *steffisburgensis* sp. n., or the same substance obtained by any
other means

sumetizidum
sumetizide

6-chloro-3,4-dihydro-3-succinimidomethyl-2*H*-1,2,4-benzothiadiazine-
7-sulfonamide 1,1-dioxide
 $C_{12}H_{13}ClN_4O_4S_2$




*Proposed International
Non-Proprietary Name
(Latin, English)*

*Chemical Name or Description,
Molecular and Graphic Formulae*


tetridaminum
tetridamine

4,5,6,7-tetrahydro-2-methyl-3-(methylamino)-2H-indazole
 $C_8H_{11}N_3$




tigestolum
tigestol

19-nor-17 α -pregn-5(10)-en-20-yn-17-ol
 $C_{28}H_{48}O$




tribenosidum
tribenoside

ethyl 3,5,6-tri-O-benzyl-D-glucufuranoside
 $C_{22}H_{34}O_8$



tropirinum
tropirine

3 α -[(5H-benzo[4.5]cyclohepta[1.2-b]pyridyl)-5-oxy]tropane
 $C_{22}H_{21}N_2O$



CORRIGENDA

Vol. 20, No. 6

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 16

p. 223: *delete*

sulformetoxinum
sulformetoxine

insert

sulfadoxinum
sulfadoxine


Vol. 22, No. 3

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 19

p. 117: *delete*

fenclexonii bromidum
fenclexonium bromide


1-(3,3-diphenylpropyl)-1-methylpiperidinium bromide
 $C_{21}H_{32}BrN$



insert

fenclexonii metilsulfas
fenclexonium metilsulfate

1-[3-(1-cyclohexenyl)-3-phenylpropyl]-1-methylpiperidinium methylsulfate
 $C_{32}H_{35}NO_4S$



p. 122: *delete*

penoctonii bromidum
penoctonium bromide

diethyl(2-hydroxyethyl)octyl ammonium bromide diphenylacetate
 $C_{26}H_{53}BrNO_2$

insert

penoctonii bromidum
penoctonium bromide

diethyl(2-hydroxyethyl)octyl ammonium bromide dicyclopentylacetate
 $C_{24}H_{50}BrNO_2$

Annex

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS *

The following procedure shall be followed by the World Health Organization in the selection of recommended international non-proprietary names for pharmaceutical preparations, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international non-proprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Non-proprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical preparation shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international non-proprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*¹ and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

(i) set forth the name under consideration;

(ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;

(iii) identify the substance for which a name is being considered;

(iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

(v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.

A. Such objection shall:

(i) identify the person objecting;

(ii) state his interest in the name;

(iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international non-proprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3).

¹ The title of this publication was changed to *WHO Chronicle* in January 1959.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international non-proprietary name.

8. In forwarding a recommended international non-proprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the non-proprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PRÉPARATIONS *

1. Names should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names already in common use.

2. The name of a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided.

The above primary principles are to be implemented by utilization of the following secondary principles.

3. In devising the name of the first substance in a new pharmacological group (the parent substance), consideration should be given to the possibility of devising suitable names for related substances belonging to the new group.

4. Syllables such as "methylhydro", "methoxy" and "chlor" should preferably be abbreviated (to "medro", "meto", "clo", etc.).

5. In the naming of substances which are acids, existing names generally used in chemistry which include the word "acidum" ("acid") should be used, if the name is adequate for practical use in therapy and pharmacy. In other circumstances, the substance should be named by a single word and not by a name which includes the word "acid". Where the word "acid" is not used in the name, as is customary in the penicillin series, a salt should preferably be named without modification of the parent acid name, e.g., "oxacillin" and "oxacillin sodium".

6. Names for substances which are used as salts should in general apply to the active base (or the active acid). Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid (or the inactive base). Exceptions may have to be made for those cases in which pharmacological activity may reside in both parts of the salt or ester.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

7. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

8. To facilitate translation and pronunciation "f" should preferably be used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y".

9. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

10. Group relationship in names (see item 2) should preferably be shown by using common syllables in the following list. Where a syllable or a group of syllables is shown without any hyphens it may be used anywhere in the name. The syllable, or group of syllables, should, if possible, be used only for such substances.

* Text revised by the Expert Committee on Non-Proprietary Names for Pharmaceutical Preparations (unpublished reports WHO/Pharm/67.443 and WHO/Pharm/68.447).

Subsidiary group relationships should be shown by devising names which show similarities to and are analogous with a previously named substance, the parent substance.

At the end of the list are general chemical syllables. Should they come into conflict with other suggested syllables, the suffix conveying the best information should be used.

<i>Latin</i>	<i>English</i>	<i>French</i>	
-andr-	-andr-	-andr-	} steroids, androgenic
or -stan-	or -stan-	or -stan-	
or -ster-	or -ster-	or -ster-	
-apol-	-apol-	-apol-	polysulfonic anticoagulants
-arolum	-arol	-arol	anticoagulants
-bamatum	-bamate	-bamate	tranquillizers of the propanediol and pentanediol series
barb	barb	barb	barbituric acids, hypnotic activity
bol	bol	bol	anabolic steroids
-cainum	-caine	-caine	local anaesthetics
cef-	cef-	cef-	antibiotics with cefalosporanic acid nucleus
-cillinum	-cillin	-cilline	penicillins: derivatives of carboxy-6-amino-penicillanic acid
-cort-	-cort-	-cort-	steroids, glucocorticoids and mineralocorticoids, other than prednisolone derivatives
crinum	-crine	-crine	acridine derivatives
-curonium	-curonium	-curonium	curare-like drugs
-cyclinum	-cycline	-cycline	antibiotics, tetracycline derivatives
-dionum	-dione	-dione	antiepileptics derived from oxazolidinedione
-estr-	-estr-	-estr-	estrogenic drugs.
-gest-	-gest-	-gest-	steroids, progestative
gli-	gli-	gli-	sulfonamide oral antidiabetics
io-	io-	io-	iodine-containing contrast media
-mer-	-mer-	-mer-	mercury-containing drugs, antimicrobial or diuretic
mito-	mito-	mito-	nucleotoxic, antineoplastic agents
-moxinum	-moxin	-moxine	monoamine oxidase inhibitors
-mycinum	-mycin	-mycine	antimicrobial antibiotics, produced by <i>Streptomyces</i> strains
nifur-	nifur-	nifur-	5-nitrofur derivatives
-orexum	-orex	-orex	anorexigenic agents
-praminum	-pramine	-pramine	dibenzazepine, compounds of the imipramine type
-quinum	-quine	-quine	quinoline derivatives
-serpinum	-serpine	-serpine	derivatives of <i>Rauwolfia</i> alkaloids
-stigminum	-stigmine	-stigmine	anticholinesterases
sulfa-	sulfa-	sulfa-	sulfonamides, used as antimicrobials
-tizidum	-tizide	-tizide	diuretics which are thiazide derivatives
-toinum	-toin	-toine	antiepileptics which are hydantoin derivatives
-verinum	-verine	-vérine	spasmolytics with a papaverine-like action
-inum	-ine	-ine	alkaloids and organic bases
-onum	-one	-one	ketones
-ium	-ium	-ium	quaternary amines